Get to know our clinical trials

Clinical trial to evaluate the efficacy and safety of TheraSphereTM followed by durvalumab (Imfinzi®) with tremelimumab, versus the use of TheraSphereTM in monotherapy for hepatocellular carcinoma (HCC)

THE PURPOSE OF THE STUDY IS TO TEST A NEW TREATMENT FOR YOUR DISEASE. YOUR DOCTOR HAS DETERMINED THAT THERASPHERETM IS AN APPROPRIATE TREATMENT OPTION FOR YOU. THE STUDY WILL DETERMINE WHETHER IT IS SAFE TO ADD THE DRUGS DURVALUMAB AND TREMELIMUMAB AS IMMUNOTHERAPY AFTER TREATMENT WITH THERASPHERETM AND WHETHER THIS ADDITION IMPROVES THE RESULTS SEEN WITH THERASPHERETM AS MONOTHERAPY.

Director Hepatology Unit
Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • RANDOMIZED, PROSPECTIVE, MULTICENTER, OPEN-LABEL, PROSPECTIVE CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF THERASPHERETM FOLLOWED BY DURVALUMAB (IMFINZI®) WITH TREMELIMUMAB, VERSUS THE USE OF THERASPHERETM AS MONOTHERAPY FOR HEPATOCELLULAR CARCINOMA (HCC). IMMUNOTHERAPY
  • Code EudraCT: 2021-001907-33
  • Protocol number: S2472
  • Promoter: Boston scientific
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.